Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza

FDA approves Teva’s once-monthly schizophrenia treatment

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that eliminates the need for daily medication.

Teva wins FDA approval for monthly schizophrenia injection Weltruza

Teva has received FDA approval for once monthly injectable schizophrenia drug Weltruza. The announcement sent Teva shares gaining in premarket.

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

WELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses,

Teva Pharmaceutical Industries wins WELTRUZA approval

FDA approved Teva's monthly WELTRUZA for adults with schizophrenia; three strengths are expected in the U.S. in the coming weeks.

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For ...

WELTRUZA™(olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring requiredThe approval is based…